Page 5 - Specific Cases News Today

FDA Breakthrough Therapy Designation in MAGE-A4 expressing patients. The Synovial Sarcoma market is expected to show positive growth, mainly ascribed to the increased prevalence and the anticipated launch of novel therapies, such as Anlotinib, ADP-A2M4, For further information on Market Impact by Therapies, visit: Synovial Sarcoma, also known as malignant synovioma, can originate from different soft tissue types, such as muscle or ligaments. It is a high-grade tumor and spreads to distant si...